| Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ... New England Journal of Medicine 386 (16), 1532-1546, 2022 | 1960 | 2022 |
| Duration of protection against mild and severe disease by Covid-19 vaccines N Andrews, E Tessier, J Stowe, C Gower, F Kirsebom, R Simmons, ... New England Journal of Medicine 386 (4), 340-350, 2022 | 581 | 2022 |
| Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England N Andrews, J Stowe, F Kirsebom, S Toffa, R Sachdeva, C Gower, ... Nature medicine 28 (4), 831-837, 2022 | 358 | 2022 |
| Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ... MedRxiv, 2021.12. 14.21267615, 2021 | 260 | 2021 |
| Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK N Andrews, E Tessier, J Stowe, C Gower, F Kirsebom, R Simmons, ... medrxiv, 2021.09. 15.21263583, 2021 | 180 | 2021 |
| COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England FCM Kirsebom, N Andrews, J Stowe, S Toffa, R Sachdeva, E Gallagher, ... The Lancet Infectious Diseases 22 (7), 931-933, 2022 | 165 | 2022 |
| Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study J Stowe, N Andrews, F Kirsebom, M Ramsay, JL Bernal Nature communications 13 (1), 5736, 2022 | 121 | 2022 |
| Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection MS Habibi, RS Thwaites, M Chang, A Jozwik, A Paras, F Kirsebom, ... Science 370 (6513), eaba9301, 2020 | 115 | 2020 |
| Neutrophils in respiratory viral infections C Johansson, FCM Kirsebom Mucosal immunology 14 (4), 815-827, 2021 | 87 | 2021 |
| Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study N Andrews, J Stowe, F Kirsebom, C Gower, M Ramsay, JL Bernal Medrxiv, 2021.11. 15.21266341, 2021 | 76 | 2021 |
| Effectiveness of BNT162b2 against COVID-19 in adolescents AA Powell, F Kirsebom, J Stowe, K McOwat, V Saliba, ME Ramsay, ... The Lancet Infectious Diseases 22 (5), 581-583, 2022 | 60 | 2022 |
| Protection against symptomatic infection with delta (B. 1.617. 2) and omicron (B. 1.1. 529) BA. 1 and BA. 2 SARS-CoV-2 variants after previous infection and vaccination in … AA Powell, F Kirsebom, J Stowe, ME Ramsay, J Lopez-Bernal, N Andrews, ... The Lancet Infectious Diseases 23 (4), 435-444, 2023 | 57 | 2023 |
| Neutrophil recruitment and activation are differentially dependent on MyD88/TRIF and MAVS signaling during RSV infection FCM Kirsebom, F Kausar, R Nuriev, S Makris, C Johansson Mucosal immunology 12 (5), 1244-1255, 2019 | 55 | 2019 |
| Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA. 4 and BA. 5 in England FCM Kirsebom, N Andrews, J Stowe, N Groves, M Chand, M Ramsay, ... The Lancet Regional Health–Europe 23, 2022 | 33* | 2022 |
| High‐throughput transposon sequencing highlights the cell wall as an important barrier for osmotic stress in methicillin resistant Staphylococcus aureus and … CF Schuster, DM Wiedemann, FCM Kirsebom, M Santiago, S Walker, ... Molecular microbiology 113 (4), 699-717, 2020 | 33 | 2020 |
| Population genetic structure and adaptation of malaria parasites on the edge of endemic distribution CW Duffy, H Ba, S Assefa, AD Ahouidi, YB Deh, A Tandia, FCM Kirsebom, ... Molecular ecology 26 (11), 2880-2894, 2017 | 32 | 2017 |
| Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England FCM Kirsebom, N Andrews, R Sachdeva, J Stowe, M Ramsay, ... Nature Communications 13 (1), 7688, 2022 | 30 | 2022 |
| Neutrophils do not impact viral load or the peak of disease severity during RSV infection F Kirsebom, C Michalaki, M Agueda-Oyarzabal, C Johansson Scientific Reports 10 (1), 1110, 2020 | 28 | 2020 |
| Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA. 1 boosters against COVID-19 hospitalisation in England: a test-negative case … FCM Kirsebom, N Andrews, J Stowe, M Ramsay, JL Bernal The Lancet Infectious Diseases 23 (11), 1235-1243, 2023 | 25 | 2023 |
| Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England AA Powell, F Kirsebom, J Stowe, K McOwat, V Saliba, ME Ramsay, ... MedRxiv, 2021.12. 10.21267408, 2021 | 24 | 2021 |
